Safeguard Scientifics Inc. (NYSE:SFE)’s share price was down 4.1% during mid-day trading on Friday . The stock traded as low as $12.73 and last traded at $12.77, with a volume of 52,784 shares changing hands. The stock had previously closed at $13.31.

Separately, Zacks Investment Research upgraded Safeguard Scientifics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Tuesday, June 14th.

The firm’s market cap is $262.70 million. The stock has a 50-day moving average of $12.42 and a 200-day moving average of $12.90.

Safeguard Scientifics (NYSE:SFE) last announced its earnings results on Thursday, July 28th. The company reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.45. During the same period last year, the company earned ($0.91) EPS. On average, equities analysts forecast that Safeguard Scientifics Inc. will post ($0.74) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Safeguard Scientifics stock. Bank of Montreal Can raised its stake in shares of Safeguard Scientifics Inc. (NYSE:SFE) by 3.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 542,390 shares of the company’s stock after buying an additional 19,168 shares during the period. Bank of Montreal Can owned 2.63% of Safeguard Scientifics worth $7,870,000 as of its most recent SEC filing.

Safeguard Scientifics, Inc provides capital, as well as strategic, operational and management resources to growth-stage businesses. The Company participates in early- and growth-stage financings. The Company operates through two segments: Healthcare and Technology. The Healthcare segment’s companies focuses principally on medical technology (MedTech), including diagnostics and devices, and healthcare technology (HealthTech).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.